Vimarsana
Biggest News Aggregation in the World

Page 11 - Pfizer Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pfizer Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pfizer Ventures Today - Breaking & Trending Today

Storm Therapeutics Closes USD $30M Series B Financing - Vimarsana News

Storm Therapeutics Closes USD $30M Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Anjarium Biosciences appoints ex-Novartis gene therapy leader Otmane Boussif, DSc as Chief Technology Officer - Vimarsana News

Anjarium Biosciences appoints ex-Novartis gene therapy leader Otmane Boussif, DSc as Chief Technology Officer

ZURICH, Dec. 8, 2022 /PRNewswire/ -- Anjarium Biosciences AG ("Anjarium"), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announces the appointment

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study - Vimarsana News

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study

/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying...

Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform - Vimarsana News

Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform

/PRNewswire/ -- Jnana Therapeutics ("Jnana"), a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for...

Nucleome Therapeutics raises oversubscribed £37.5 million - Vimarsana News

Nucleome Therapeutics raises oversubscribed £37.5 million

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class...